Quote this publication Share Print

ARGANOVA

-
Opinions on drugs - Posted on Nov 16 2011

Reason for request

Inclusion on the list of medicines approved for hospital use.

-


Clinical Benefit

Substantial

The actual benefit of ARGANOVA (argatroban) is substantial.


Clinical Added Value

no clinical added value

ARGANOVA does not provide an improvement in actual benefit (IAB level V) in the treatment of adult patients with heparin-induced thrombocytopenia (HIT) type II, requiring parenteral anti-thrombotic treatment.


Contact Us

Évaluation des médicaments